Drug Pipeline
Breakthrough Therapies and New Biologics Feature in the Gene Therapy Pipeline More
Briefing
“Drug Pipeline”
26 result(s)
Drug Pipeline
New migraine drugs are closer to approval and expanding treatment choices for many patients More
Briefing
Cost Management
Assessing New-to-Market Biologics and Biosimilars
CVS Health offers strategies for addressing new-to-market products to ensure access to clinically appropriate insulin or other medications. More
Commentary
Specialty
Medications that have been used to treat diabetes are now being used for weight loss in patients without diabetes. But do the outcomes justify the costs? More
Briefing
Drug Pipeline
Biosimilars help to increase market competition. Balancing the use of biosimilars and biologics with strategic formulary decisions deliver lower costs. More
Briefing
Care Management
Biogen’s new Alzheimer’s drug may be changing the treatment landscape, but lingering questions remain. More
Commentary
Drug Pipeline
Effective management strategies can help payors manage cost for a range of new treatment options in the drug pipeline. Several medications are nearing approvals for Alzheimer’s,... More
Briefing
Drug Pipeline
A range of new treatment options for AD are expected to come to market in the next couple years. Effective management strategies can help payors manage cost. More
Briefing
Specialty
Our proven strategies including step therapy, Specialty Guideline Management, and cross-benefit management can help clients better manage costs for the growing number of IBD... More
Feature
Drug Pipeline
Over the past dozen years, several new treatments have come to market with the first oral preventive expected to be approved in December. Targeted management to help balance... More
Feature